# Rebif New Formulation (RNF) Quality of Life (QOL) Study

> **NCT00472797** · PHASE3 · COMPLETED · sponsor: **EMD Serono** · enrollment: 232 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Rebif New Formulation Non Titrated
- **DRUG:** Rebif New Formulation Titrated

## Key facts

- **NCT ID:** NCT00472797
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2009-02
- **Final completion:** 2009-11
- **Target enrollment:** 232 (ACTUAL)
- **Last updated:** 2013-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00472797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00472797, "Rebif New Formulation (RNF) Quality of Life (QOL) Study". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00472797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*